Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 firibastat study in difficult-to-treat or resistant hypertension
NL-OMON52137Phase 3Active, not recruiting
- Sponsor
- Quantum Genomics
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and essential hypertension comparing Firibastat then open-label firibastat with Placebo then open-label firibastat (2 arms). Primary endpoint: Change from baseline in systolic automated office blood pressure at Week 12. Started Jul 2022; status: active, not recruiting.
02
Drugs
firibastat
03
Conditions
hypertension (HTN)essential hypertension
Beyond the preview
Go deeper on NL-OMON52137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52137.